Press Releases

Year

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phase 1 dose escalation

Nov 18, 2024

PDF Version

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated

Nov 08, 2024

PDF Version

Immatics Announces Pricing of $150 Million Public Offering

H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten

Oct 10, 2024

PDF Version

Immatics Announces Proposed $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of

Oct 10, 2024

PDF Version

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data

Oct 10, 2024

PDF Version

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations

Oct 04, 2024

PDF Version

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancers Data from the first-in-human Phase 1 dose escalation trial demonstrate initial

Sep 16, 2024

PDF Version

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its

Sep 06, 2024

PDF Version

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profile Registration-enabling

Aug 13, 2024

PDF Version

Immatics Appoints Alise Reicin to Board of Directors

Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D.,

Jul 31, 2024

PDF Version

Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-concept clinical data for its

Jul 18, 2024

PDF Version

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor

May 14, 2024

PDF Version

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated Registration-enabling randomized Phase 2/3 trial for

Mar 21, 2024

PDF Version

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of

Jan 17, 2024

PDF Version

Immatics Announces Proposed Public Offering

Jan 17, 2024

PDF Version

Press Releases

Press Contact

Press Releases